Rad51c Deficiency Destabilizes XRCC3, Impairs Recombination and Radiosensitizes S/G2-Phase Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. -
Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia. -
Use of the XRCC2 Promoter for in Vivo Cancer Diagnosis and Therapy
Chen et al. Cell Death and Disease (2018) 9:420 DOI 10.1038/s41419-018-0453-9 Cell Death & Disease ARTICLE Open Access Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy Yu Chen1,ZhenLi1,ZhuXu1, Huanyin Tang1,WenxuanGuo1, Xiaoxiang Sun1,WenjunZhang1, Jian Zhang2, Xiaoping Wan1, Ying Jiang1 and Zhiyong Mao 1 Abstract The homologous recombination (HR) pathway is a promising target for cancer therapy as it is frequently upregulated in tumors. One such strategy is to target tumors with cancer-specific, hyperactive promoters of HR genes including RAD51 and RAD51C. However, the promoter size and the delivery method have limited its potential clinical applications. Here we identified the ~2.1 kb promoter of XRCC2, similar to ~6.5 kb RAD51 promoter, as also hyperactivated in cancer cells. We found that XRCC2 expression is upregulated in nearly all types of cancers, to a degree comparable to RAD51 while much higher than RAD51C. Further study demonstrated that XRCC2 promoter is hyperactivated in cancer cell lines, and diphtheria toxin A (DTA) gene driven by XRCC2 promoter specifically eliminates cancer cells. Moreover, lentiviral vectors containing XRCC2 promoter driving firefly luciferase or DTA were created and applied to subcutaneous HeLa xenograft mice. We demonstrated that the pXRCC2-luciferase lentivirus is an effective tool for in vivo cancer visualization. Most importantly, pXRCC2-DTA lentivirus significantly inhibited the growth of HeLa xenografts in comparison to the control group. In summary, our results strongly indicate that virus-mediated delivery of constructs built upon the XRCC2 promoter holds great potential for tumor diagnosis and therapy. -
FANCJ Regulates the Stability of FANCD2/FANCI Proteins and Protects Them from Proteasome and Caspase-3 Dependent Degradation
FANCJ regulates the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation Komaraiah Palle, Ph.D. (Kumar) Assistant Professor of Oncologic Sciences Abraham Mitchell Cancer Research Scholar Mitchell Cancer Institute University of South Alabama Outline • Fanconi anemia (FA) pathway • Role of FA pathway in Genome maintenance • FANCJ and FANCD2 functional relationship • FANCJ-mediated DDR in response to Fork-stalling Fanconi Anemia • Rare, inherited blood disorder. • 1:130,000 births Guido Fanconi 1892-1979 • Affects men and women equally. • Affects all racial and ethnic groups – higher incidence in Ashkenazi Jews and Afrikaners Birth Defects Fanconi anemia pathway • FA is a rare chromosome instability syndrome • Autosomal recessive disorder (or X-linked) • Developmental abnormalities • 17 complementation groups identified to date • FA pathway is involved in DNA repair • Increased cancer susceptibility - many patients develop AML - in adults solid tumors Fanconi Anemia is an aplastic anemia FA patients are prone to multiple types of solid tumors • Increased incidence and earlier onset cancers: oral cavity, GI and genital and reproductive tract head and neck breast esophagus skin liver brain Why? FA is a DNA repair disorder • FA caused by mutations in 17 genes: FANCA FANCF FANCM FANCB FANCG/XRCC9 FANCN/PALB2 FANCC FANCI RAD51C/FANCO FANCD1/BRCA2 FANCJ SLX4/FANCP FANCD2 FANCL ERCC2/XPF/FANCQ FANCE BRCA1/FANCS • FA genes function in DNA repair processes • FA patient cells are highly sensitive -
1 AGING Supplementary Table 2
SUPPLEMENTARY TABLES Supplementary Table 1. Details of the eight domain chains of KIAA0101. Serial IDENTITY MAX IN COMP- INTERFACE ID POSITION RESOLUTION EXPERIMENT TYPE number START STOP SCORE IDENTITY LEX WITH CAVITY A 4D2G_D 52 - 69 52 69 100 100 2.65 Å PCNA X-RAY DIFFRACTION √ B 4D2G_E 52 - 69 52 69 100 100 2.65 Å PCNA X-RAY DIFFRACTION √ C 6EHT_D 52 - 71 52 71 100 100 3.2Å PCNA X-RAY DIFFRACTION √ D 6EHT_E 52 - 71 52 71 100 100 3.2Å PCNA X-RAY DIFFRACTION √ E 6GWS_D 41-72 41 72 100 100 3.2Å PCNA X-RAY DIFFRACTION √ F 6GWS_E 41-72 41 72 100 100 2.9Å PCNA X-RAY DIFFRACTION √ G 6GWS_F 41-72 41 72 100 100 2.9Å PCNA X-RAY DIFFRACTION √ H 6IIW_B 2-11 2 11 100 100 1.699Å UHRF1 X-RAY DIFFRACTION √ www.aging-us.com 1 AGING Supplementary Table 2. Significantly enriched gene ontology (GO) annotations (cellular components) of KIAA0101 in lung adenocarcinoma (LinkedOmics). Leading Description FDR Leading Edge Gene EdgeNum RAD51, SPC25, CCNB1, BIRC5, NCAPG, ZWINT, MAD2L1, SKA3, NUF2, BUB1B, CENPA, SKA1, AURKB, NEK2, CENPW, HJURP, NDC80, CDCA5, NCAPH, BUB1, ZWILCH, CENPK, KIF2C, AURKA, CENPN, TOP2A, CENPM, PLK1, ERCC6L, CDT1, CHEK1, SPAG5, CENPH, condensed 66 0 SPC24, NUP37, BLM, CENPE, BUB3, CDK2, FANCD2, CENPO, CENPF, BRCA1, DSN1, chromosome MKI67, NCAPG2, H2AFX, HMGB2, SUV39H1, CBX3, TUBG1, KNTC1, PPP1CC, SMC2, BANF1, NCAPD2, SKA2, NUP107, BRCA2, NUP85, ITGB3BP, SYCE2, TOPBP1, DMC1, SMC4, INCENP. RAD51, OIP5, CDK1, SPC25, CCNB1, BIRC5, NCAPG, ZWINT, MAD2L1, SKA3, NUF2, BUB1B, CENPA, SKA1, AURKB, NEK2, ESCO2, CENPW, HJURP, TTK, NDC80, CDCA5, BUB1, ZWILCH, CENPK, KIF2C, AURKA, DSCC1, CENPN, CDCA8, CENPM, PLK1, MCM6, ERCC6L, CDT1, HELLS, CHEK1, SPAG5, CENPH, PCNA, SPC24, CENPI, NUP37, FEN1, chromosomal 94 0 CENPL, BLM, KIF18A, CENPE, MCM4, BUB3, SUV39H2, MCM2, CDK2, PIF1, DNA2, region CENPO, CENPF, CHEK2, DSN1, H2AFX, MCM7, SUV39H1, MTBP, CBX3, RECQL4, KNTC1, PPP1CC, CENPP, CENPQ, PTGES3, NCAPD2, DYNLL1, SKA2, HAT1, NUP107, MCM5, MCM3, MSH2, BRCA2, NUP85, SSB, ITGB3BP, DMC1, INCENP, THOC3, XPO1, APEX1, XRCC5, KIF22, DCLRE1A, SEH1L, XRCC3, NSMCE2, RAD21. -
PALB2 Genetic Testing for Breast Cancer Risk
Lab Management Guidelines V2.0.2021 PALB2 Genetic Testing for Breast Cancer Risk MOL.TS.251.A v2.0.2021 Procedure addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedure(s) addressed by this Procedure code(s) guideline PALB2 Known Familial Mutation Analysis 81308 PALB2 Sequencing 81307 PALB2 Deletion/Duplication Analysis 81479 What is PALB2 genetic testing Definition Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer mortality in women around the world. Hereditary breast cancer accounts for 5% to 10% of all breast cancer cases. Screening with breast magnetic resonance imaging (MRI) is recommended for women with a greater than 20% lifetime risk for disease based on estimates of risk models that are largely dependent on family history. A large body of evidence indicates that an increased lifetime risk of >20% can also be established through genetic testing. In particular, two cancer susceptibility genes, BRCA1 and BRCA2, are implicated in about 20% of all hereditary breast cancer cases. Other genes have also been identified in the literature as being associated with inherited breast cancer risk, including ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53.1,2 In particular, PALB2 is a gene that encodes a protein that may be involved in tumor suppression, and is considered a partner and localizer of BRCA2. Specifically, ~50 truncating mutations in PALB2 have been detected among breast cancer families worldwide. -
Distinct Roles of BRCA2 in Replication Fork Protection in Response to Hydroxyurea and DNA Interstrand Cross-Links
Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links Kimberly A. Rickman,1 Raymond J. Noonan,1 Francis P. Lach,1 Sunandini Sridhar,1 Anderson T. Wang,1,5 Avinash Abhyankar,2 Athena Huang,1 Michael Kelly,3 Arleen D. Auerbach,4 and Agata Smogorzewska1 1Laboratory of Genome Maintenance, The Rockefeller University, New York, New York 10065, USA; 2New York Genome Center, New York, New York 10013, USA; 3Tufts Medical Center, Boston, Massachusetts 02111, USA; 4Human Genetics and Hematology, The Rockefeller University, New York, New York 10065, USA DNA interstrand cross-links (ICLs) are a form of DNA damage that requires the interplay of a number of repair proteins including those of the Fanconi anemia (FA) and the homologous recombination (HR) pathways. Pathogenic variants in the essential gene BRCA2/FANCD1, when monoallelic, predispose to breast and ovarian cancer, and when biallelic, result in a severe subtype of Fanconi anemia. BRCA2 function in the FA pathway is attributed to its role as a mediator of the RAD51 recombinase in HR repair of programmed DNA double-strand breaks (DSB). BRCA2 and RAD51 functions are also required to protect stalled replication forks from nucleolytic degradation during re- sponse to hydroxyurea (HU). While RAD51 has been shown to be necessary in the early steps of ICL repair to prevent aberrant nuclease resection, the role of BRCA2 in this process has not been described. Here, based on the analysis of BRCA2 DNA-binding domain (DBD) mutants (c.8488-1G>A and c.8524C>T) discovered in FA patients presenting with atypical FA-like phenotypes, we establish that BRCA2 is necessary for the protection of DNA at ICLs. -
Overexpression of Rad51c Splice Variants in Colorectal Tumors
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 11 Overexpression of Rad51C splice variants in colorectal tumors Arjun Kalvala1, Li Gao1, Brittany Aguila1, Tyler Reese1, Gregory A. Otterson1,2, Miguel A. Villalona-Calero1,2,3 and Wenrui Duan1,2 1 Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A 2 Division of Medical Oncology Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A 3 Department of Pharmacology at The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A Correspondence to: Miguel A. Villalona-Calero, email: [email protected] Correspondence to: Wenrui Duan, email: [email protected] Keywords: Rad51C isoform overexpression, Promoter methylation, Colorectal tumors Received: July 29, 2014 Accepted: December 24, 2014 Published: December 30, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Functional alterations in Rad51C are the cause of the Fanconi anemia complementation group O (FANCO) gene disorder. We have identified novel splice variants of Rad51C mRNA in colorectal tumors and cells. The alternatively spliced transcript variants are formed either without exon-7 (variant 1), without exon 6 and 7 (variant 2) or without exon 7 and 8 (variant 3). Real time PCR analysis of nine pair-matched colorectal tumors and non-tumors showed that variant 1 was overexpressed in tumors compared to matched non- tumors. -
Reduced FANCD2 Influences Spontaneous SCE and RAD51 Foci
Oncogene (2013) 32, 5338–5346 OPEN & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia P Gravells1,3, L Hoh1,2,4, S Solovieva1, A Patil1, E Dudziec1, IG Rennie2, K Sisley2 and HE Bryant1 Uveal melanoma (UM) is unique among cancers in displaying reduced endogenous levels of sister chromatid exchange (SCE). Here we demonstrate that FANCD2 expression is reduced in UM and that ectopic expression of FANCD2 increased SCE. Similarly, FANCD2-deficient fibroblasts (PD20) derived from Fanconi anaemia patients displayed reduced spontaneous SCE formation relative to their FANCD2-complemented counterparts, suggesting that this observation is not specific to UM. In addition, spontaneous RAD51 foci were reduced in UM and PD20 cells compared with FANCD2-proficient cells. This is consistent with a model where spontaneous SCEs are the end product of endogenous recombination events and implicates FANCD2 in the promotion of recombination-mediated repair of endogenous DNA damage and in SCE formation during normal DNA replication. In both UM and PD20 cells, low SCE was reversed by inhibiting DNA-PKcs (DNA-dependent protein kinase, catalytic subunit). Finally, we demonstrate that both PD20 and UM are sensitive to acetaldehyde, supporting a role for FANCD2 in repair of lesions induced by such endogenous metabolites. Together, these data suggest FANCD2 may promote spontaneous SCE by influencing which double- strand -
Contribution of DNA Double-Strand Break Repair Gene XRCC3 Genotypes to Oral Cancer Susceptibility in Taiwan
ANTICANCER RESEARCH 34: 2951-2956 (2014) Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Oral Cancer Susceptibility in Taiwan CHIA-WEN TSAI1,3, WEN-SHIN CHANG2,3, JUHN-CHERNG LIU2,3, MING-HSUI TSAI3, CHENG-CHIEH LIN3,4 and DA-TIAN BAU1,2,3 Graduate Institutes of 1Basic Medical Science and 2Clinic Medical Science, China Medical University, Taichung, Taiwan, R.O.C.; 3Terry Fox Cancer Research Laboratory, Department of Medical Research, in China Medical University Hospital, Taichung, Taiwan, R.O.C.; 4Asia University, Taichung, Taiwan, R.O.C. Abstract. The DNA repair gene X-ray repair cross and neck cancers in Taiwan (2). Three major lifestyle factors, complementing protein 3 (XRCC3) is thought to play a major namely the use of tobacco, alcohol and betel nuts, are main role in double-strand break repair and in maintaining causes of oral cancer in Taiwan, while the genomic etiology genomic stability. Very possibly, defective double-strand of oral cancer is of great interest but largely unknown. break repair of cells can lead to carcinogenesis. Therefore, a Human DNA repair mechanisms protect the genome from case–control study was performed to reveal the contribution various insults caused by endogenous and exogenous DNA- of XRCC3 genotypes to individual oral cancer susceptibility. damaging agents (3) and defects in the DNA repair system In this hospital-based research, the association of XRCC3 are thought to be essential in tumorigenesis (4, 5). Therefore, rs1799794, rs45603942, rs861530, rs3212057, rs1799796, it is logical to suspect that some genetic variants of DNA rs861539, rs28903081 genotypes with oral cancer risk in a repair genes might contribute to oral cancer pathogenesis. -
A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family
Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase. -
(EZH2) Genotypes with Bladder Cancer Risk in Taiwan
ANTICANCER RESEARCH 36 : 4509-4514 (2016) doi:10.21873/anticanres.10997 Association of Enhancer of Zeste 2 ( EZH2 ) Genotypes with Bladder Cancer Risk in Taiwan WEN-SHIN CHANG 1,2* , CHENG-HSI LIAO 1,2,3,8* , CHIA-WEN TSAI 2* , PEI-SHIN HU 2,4 , HSI-CHIN WU 2, SHIH-WEI HSU 1,2,3,8 , CHIEH-LUN HSIAO 1,2 , CHANG-HSIEN HSU 5, YI-WEN HUNG 6 and DA-TIAN BAU 1,2,7 1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.; 2Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.; 3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.; 4Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.; Departments of 5Business Administration, and 7Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.; 6Department of Medicine Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; 8National Defence Medical Center, Taipei, Taiwan, R.O.C. Abstract. Aim: Bladder cancer is the sixth most common associated with the lower risk of bladder cancer development, cancer worldwide and its incidence is particularly high in especially among non-smokers. many developed regions including southwestern Taiwan. However, the genetic contribution to the etiology of bladder Bladder cancer is the most serious urinary neoplasm cancer is not well-understood. The aim of this study was to worldwide, with high incidence rates of approximately evaluate the association of the enhancer of zeste homolog 2 10/100,000 and 3/100,000 in more and less developed (EZH2) genotypes with Taiwan bladder cancer risk.